Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharm Biopharm ; 199: 114298, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38642716

ABSTRACT

Delivering drugs to the brain is a complex challenge in medical research, particularly for disorders like Alzheimer's and Parkinson's. The blood-brain barrier restricts the entry of many therapeutic molecules, hindering their effectiveness. Nanoparticles, a potential solution, face issues like toxicity and limited approvals. A new avenue explores the use of small extracellular vesicles (sEVs), i.e., exosomes, as natural carriers for drug delivery. sEVs, tiny structures below 150 nm, show promise due to their minimal immune response and ability to precisely deliver drugs. This review focuses on the potential of sEVs-based drug delivery systems for treating neurological disorders, brain cancers, and other brain-related issues. Notably, bioengineered sEVs-carrying therapeutic compounds exhibit promise in early studies. The unique features of sEVs, such as their small size and natural properties, position them as candidates to overcome challenges in drug delivery to the brain. Ongoing clinical trials and research into sEVs behavior within the body further highlight their potential for revolutionizing drug delivery and addressing complex brain conditions.


Subject(s)
Blood-Brain Barrier , Brain Diseases , Drug Delivery Systems , Exosomes , Humans , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/drug effects , Exosomes/metabolism , Drug Delivery Systems/methods , Brain Diseases/drug therapy , Animals , Drug Carriers/chemistry , Nanoparticles/chemistry , Brain/metabolism , Brain/drug effects
2.
Int J Biol Macromol ; 241: 124582, 2023 Jun 30.
Article in English | MEDLINE | ID: mdl-37116843

ABSTRACT

In the past few decades, substantial advancement has been made in nucleic acid (NA)-based therapies. Promising treatments include mRNA, siRNA, miRNA, and anti-sense DNA for treating various clinical disorders by modifying the expression of DNA or RNA. However, their effectiveness is limited due to their concentrated negative charge, instability, large size, and host barriers, which make widespread application difficult. The effective delivery of these medicines requires safe vectors that are efficient & selective while having non-pathogenic qualities; thus, nanomaterials have become an attractive option with promising possibilities despite some potential setbacks. Nanomaterials possess ideal characteristics, allowing them to be tuned into functional bio-entity capable of targeted delivery. In this review, current breakthroughs in the non-viral strategy of delivering NAs are discussed with the goal of overcoming challenges that would otherwise be experienced by therapeutics. It offers insight into a wide variety of existing NA-based therapeutic modalities and techniques. In addition to this, it provides a rationale for the use of non-viral vectors and a variety of nanomaterials to accomplish efficient gene therapy. Further, it discusses the potential for biomedical application of nanomaterials-based gene therapy in various conditions, such as cancer therapy, tissue engineering, neurological disorders, and infections.


Subject(s)
Genetic Therapy , Nanoparticle Drug Delivery System , Nanostructures , Nucleic Acids , Animals , Humans , Dendrimers/chemistry , Drug Stability , Genetic Therapy/methods , Hydrogels/chemistry , Liposomes/chemistry , Nanostructures/administration & dosage , Nanostructures/chemistry , Nanostructures/therapeutic use , Nucleic Acids/administration & dosage , Nucleic Acids/genetics , Nucleic Acids/metabolism , Nucleic Acids/therapeutic use , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...